A proteomic study of myeloproliferative neoplasms using reverse-phase protein arrays

References

• Delhommeau F, Pisani DF, James C, et al. Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci. 2006;63(24):2939–2953.
   PubMed Web of Science ®Google Scholar
• Adamson JW, Fialkow PJ, Murphy S, et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976;295(17):913–916.
   PubMed Web of Science ®Google Scholar
• Skoda R. The genetic basis of myeloproliferative disorders. Hematol Am Soc Hematol Educ Program. 2007;2007(1):1–10.
   Google Scholar
• Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85–109.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (London, England). 2005;365(9464):1054–1061.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–397.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–1790.
   PubMed Web of Science ®Google Scholar
• Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280(24):22788–22792.
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Jeziorowska D, Marzac C, et al. Molecular aspects of myeloproliferative neoplasms. Int J Hematol. 2010;91(2):165–173.
   PubMed Web of Science ®Google Scholar
• Pikman Y, Levine RL. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. Curr Opin Oncol. 2007;19(6):628–634.
   PubMed Web of Science ®Google Scholar
• Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene. 2007;26(47):6724–6737.
   PubMed Web of Science ®Google Scholar
• Cleary C, Kralovics R. Molecular basis and clonal evolution of myeloproliferative neoplasms. Clin Chem Lab Med. 2013;51(10):1889–1896.
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Delhommeau F, Constantinescu SN, et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723–1735.
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405.
   PubMed Web of Science ®Google Scholar
• Clinton A, McMullin MF. The Calreticulin gene and myeloproliferative neoplasms. J Clin Pathol. 2016;69(10):841–845.
   PubMed Web of Science ®Google Scholar
• Puigdecanet E, Espinet B, Lozano JJ, et al. Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia. Leukemia. 2008;22(7):1368–1376.
   PubMed Web of Science ®Google Scholar
• Berkofsky-Fessler W, Buzzai M, Kim MK, et al. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clin Cancer Res. 2010;16(17):4339–4352.
   PubMed Web of Science ®Google Scholar
• Chen E, Beer PA, Godfrey AL, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010;18(5):524–535.
   PubMed Web of Science ®Google Scholar
• Tognon R, Gasparotto EP, Leroy JM, et al. Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases. J Clin Pathol. 2011;64(1):75–82.
   PubMed Web of Science ®Google Scholar
• Rice KL, Lin X, Wolniak K, et al. Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer J. 2011;1(11):e40.
   PubMedGoogle Scholar
• Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13(4):227–232.
   PubMed Web of Science ®Google Scholar
• Charboneau L, Tory H, Chen T, et al. Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic. 2002;1(3):305–315.
   PubMedGoogle Scholar
• Ornatsky OI, Kinach R, Bandura DR, et al. Development of analytical methods for multiplex bio-assay with inductively coupled plasma mass spectrometry. J Anal At Spectrom. 2008;23(4):463–469.
   PubMed Web of Science ®Google Scholar
• Hui W, Ye F, Zhang W, et al. Aberrant expression of signaling proteins in essential thrombocythemia. Ann Hematol. 2013;92(9):1229–1238.
   PubMed Web of Science ®Google Scholar
• van Oostrum J, Calonder C, Rechsteiner D, et al. Tracing pathway activities with kinase inhibitors and reverse phase protein arrays. Proteomics Clin Appl. 2009;3(4):412–422.
   PubMed Web of Science ®Google Scholar
• Martiny-Baron G, Haasen D, D'Dorazio D, et al. Characterization of kinase inhibitors using reverse phase protein arrays. Methods Mol Biol (Clifton, NJ). 2011;785:79–107.
   PubMedGoogle Scholar
• R Team C. Team RDC.R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012.
   Google Scholar
• Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S, Sato Y, et al. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40(Database issue):D109–14.
   PubMed Web of Science ®Google Scholar
• Gabriel KR. The biplot graphic display of matrices with application to principal component analysis. Biometrika. 1971;58(3):453–467.
   Web of Science ®Google Scholar
• Bauer DF. Constructing confidence sets using rank statistics. J Am Stat Assoc. 1972;67(339):687–690.
   Web of Science ®Google Scholar
• Tiit E-M. Nonparametric statistical methods. Myles Hollander and Douglas A. Wolfe, Wiley, Chichester, 1999. No. of pages: xiii + 779. Price: £39.95. ISBN 0-471-19045-4. Statist Med. 2000;19(10):1386–1388.
   Google Scholar
• Teofili L, Martini M, Cenci T, et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer. 2008;123(7):1586–1592.
   PubMed Web of Science ®Google Scholar
• Walters DK, Goss VL, Stoffregen EP, et al. Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk Res. 2006;30(9):1097–1104.
   PubMed Web of Science ®Google Scholar
• Nagao T, Kurosu T, Umezawa Y, et al. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. PLoS One. 2014;9(1):e84746
   PubMed Web of Science ®Google Scholar
• Gallardo M, Barrio S, Fernandez M, et al. Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera. Mol Cancer. 2013;12:142.
   PubMed Web of Science ®Google Scholar
• Fisher DAC, Malkova O, Engle EK, et al. Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia. 2017;31(9):1962–1974.
   PubMed Web of Science ®Google Scholar
• Gasparotto EPL, Tognon R, Ferreira AF, et al. Deregulated expression of A1, Bcl-2, Bcl-xL, and Mcl-1 antiapoptotic proteins and Bid, Bad, and Bax proapoptotic genes in polycythemia vera patients. Braz J Pharm Sci. 2011;47(4):873–886.
   Web of Science ®Google Scholar
• Nunes NS, Tognon R, Moura LG, et al. Differential expression of apoptomiRs in myeloproliferative neoplasms. Leuk Lymphoma. 2013;54(9):2047–2051.
   PubMed Web of Science ®Google Scholar
• Tognon R, Gasparotto EP, Neves RP, et al. Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in essential thrombocythemia and myelofibrosis. J Hematol Oncol. 2012;5:2.
   PubMed Web of Science ®Google Scholar
• Rubert J, Qian Z, Andraos R, et al. Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival. BMC Cancer. 2011;11:24.
   PubMed Web of Science ®Google Scholar
• Walz C, Ahmed W, Lazarides K, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood. 2012;119(15):3550–3560.
   PubMed Web of Science ®Google Scholar
• Yan D, Hutchison RE, Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood. 2012;119(15):3539–3549.
   PubMed Web of Science ®Google Scholar
• Sakr H, Clark Schneider K, Murugesan G, et al. pSTAT3/pSTAT5 signaling patterns in molecularly defined subsets of myeloproliferative neoplasms. Appl Immunohistochem Mol Morphol. 2018;26(2):147–152.
   PubMedGoogle Scholar
• Aboudola S, Murugesan G, Szpurka H, et al. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol. 2007;31(2):233–239.
   PubMed Web of Science ®Google Scholar
• Haupt Y, Maya R, Kazaz A, et al. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296–299.
   PubMed Web of Science ®Google Scholar
• Zhou BP, Liao Y, Xia W, et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001;3(11):973–982.
   PubMed Web of Science ®Google Scholar
• Nakatake M, Monte-Mor B, Debili N, et al. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene. 2012;31(10):1323–1333.
   PubMed Web of Science ®Google Scholar
• Wilusz M, Majka M. Role of the Wnt/beta-catenin network in regulating hematopoiesis. Arch Immunol Ther Exp (Warsz).). 2008;56(4):257–266.
   PubMed Web of Science ®Google Scholar
• Jauregui MP, Sanchez SR, Ewton AA, et al. The role of beta-catenin in chronic myeloproliferative disorders. Hum Pathol. 2008;39(10):1454–1458.
   PubMed Web of Science ®Google Scholar
• Guo J, Roberts L, Chen Z, et al. JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL. PLOS One. 2015;10(3):e0114363
   PubMed Web of Science ®Google Scholar
• Treliński J, Chojnowski K, Cebula-Obrzut B, et al. Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy. Med Oncol. 2012;29(4):2388–2395.
   PubMed Web of Science ®Google Scholar
• Will B, Siddiqi T, Jorda MA, et al. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood. 2010;115(14):2901–2909.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Tefferi A, Lasho TS, et al. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia. 2006;20(10):1800–1808.
   PubMed Web of Science ®Google Scholar
• Florena AM, Tripodo C, Di Bernardo A, et al. Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis. J Clin Pathol. 2009;62(4):331–338.
   PubMed Web of Science ®Google Scholar
• Tenedini E, Fagioli ME, Vianelli N, et al. Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. Blood. 2004;104(10):3126–3135.
   PubMed Web of Science ®Google Scholar
• Zeuner A, Pedini F, Signore M, et al. Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood. 2006;107(9):3495–3502.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao H, Sun A, et al. Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia. Haematologica. 2004;89(10):1199–1206.
   PubMed Web of Science ®Google Scholar
• Maraldi T, Bertacchini J, Benincasa M, et al. Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia. Int J Oncol. 2011;38(2):427–435.
   PubMed Web of Science ®Google Scholar
• Escher C, Lochmuller H, Fischer D, et al. Reverse protein arrays as novel approach for protein quantification in muscular dystrophies. Neuromuscul Disord. 2010;20(5):302–309.
   PubMed Web of Science ®Google Scholar